Aclarion Reports 141% Scan Volume Growth as U.S. Market Access Push Begins — Aclarion, Inc.

Event summary

141% year-over-year scan volume growth in H1 2026, with 71% sequential increase.
Launched U.S. Market Access Program with PRIA Healthcare to expand payer coverage for Nociscan.
$16.3M cash position as of June 30, 2026 with no debt and runway into second half of 2027.
Added new AI-focused patent, bringing total issued/pending patents to 65 worldwide.
CLARITY trial progressing with multiple new trial sites added.

The big picture

Aclarion's accelerating scan volumes demonstrate growing physician acceptance of Nociscan's diagnostic capabilities. The U.S. Market Access Program represents a critical strategic shift toward payer coverage, which will determine the technology's scalability in the world's largest healthcare market. With $16.3M cash runway and expanding patent portfolio, Aclarion is positioning itself for evidence-driven commercial expansion.

What we're watching

Reimbursement Momentum: Whether U.K. payer coverage gains with Vitality, AXA and Aviva can be replicated in the larger U.S. market through PRIA partnership.
Trial Readout Impact: How CLARITY trial results may accelerate physician adoption and payer negotiations for Nociscan technology.
Commercial Scaling: The pace at which 141% scan volume growth can be sustained as Aclarion transitions from early validation to broader market penetration.